The Crucial Role of (E)-6-Iodo-3-[2-(pyridin-2-yl)ethenyl]-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole in Cancer Drug Synthesis
In the realm of pharmaceutical development, the precision and quality of chemical intermediates are paramount, especially when crafting life-saving medications. One such vital compound is (E)-6-Iodo-3-[2-(pyridin-2-yl)ethenyl]-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole, identified by its CAS number 886230-77-9. This light yellow solid is not merely a chemical entity; it is a critical building block in the synthesis of Axitinib, a powerful targeted therapy drug used in the treatment of various cancers, particularly renal cell carcinoma.
Axitinib functions as a selective inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases, effectively blocking angiogenesis and inhibiting tumor growth. The precise molecular structure of intermediates like (E)-6-Iodo-3-[2-(pyridin-2-yl)ethenyl]-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole dictates the efficacy and safety of the final active pharmaceutical ingredient (API). Therefore, understanding its properties and ensuring its high purity is essential for pharmaceutical manufacturers. As a reputable supplier, NINGBO INNO PHARMCHEM CO.,LTD. emphasizes the consistent quality of this Axitinib intermediate, understanding its role in achieving therapeutic success. The ability to consistently produce this compound with minimal impurities is a testament to our advanced manufacturing capabilities and commitment to the pharmaceutical industry.
The chemical and physical characteristics of (E)-6-Iodo-3-[2-(pyridin-2-yl)ethenyl]-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole, including its melting point of 156-159°C and its stable form as a light yellow solid, are indicative of its suitability for complex synthetic pathways. Sourcing high-quality intermediates is a cornerstone of successful pharmaceutical synthesis. For companies engaged in the development of oncology drugs, partnering with a reliable Axitinib intermediates manufacturer in China, such as NINGBO INNO PHARMCHEM CO.,LTD., provides the assurance of quality and timely delivery needed to keep production pipelines moving forward. This ensures that the critical journey from laboratory synthesis to patient treatment is supported by the best available chemical components.
Axitinib functions as a selective inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases, effectively blocking angiogenesis and inhibiting tumor growth. The precise molecular structure of intermediates like (E)-6-Iodo-3-[2-(pyridin-2-yl)ethenyl]-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole dictates the efficacy and safety of the final active pharmaceutical ingredient (API). Therefore, understanding its properties and ensuring its high purity is essential for pharmaceutical manufacturers. As a reputable supplier, NINGBO INNO PHARMCHEM CO.,LTD. emphasizes the consistent quality of this Axitinib intermediate, understanding its role in achieving therapeutic success. The ability to consistently produce this compound with minimal impurities is a testament to our advanced manufacturing capabilities and commitment to the pharmaceutical industry.
The chemical and physical characteristics of (E)-6-Iodo-3-[2-(pyridin-2-yl)ethenyl]-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole, including its melting point of 156-159°C and its stable form as a light yellow solid, are indicative of its suitability for complex synthetic pathways. Sourcing high-quality intermediates is a cornerstone of successful pharmaceutical synthesis. For companies engaged in the development of oncology drugs, partnering with a reliable Axitinib intermediates manufacturer in China, such as NINGBO INNO PHARMCHEM CO.,LTD., provides the assurance of quality and timely delivery needed to keep production pipelines moving forward. This ensures that the critical journey from laboratory synthesis to patient treatment is supported by the best available chemical components.
Perspectives & Insights
Core Pioneer 24
“This light yellow solid is not merely a chemical entity; it is a critical building block in the synthesis of Axitinib, a powerful targeted therapy drug used in the treatment of various cancers, particularly renal cell carcinoma.”
Silicon Explorer X
“Axitinib functions as a selective inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases, effectively blocking angiogenesis and inhibiting tumor growth.”
Quantum Catalyst AI
“The precise molecular structure of intermediates like (E)-6-Iodo-3-[2-(pyridin-2-yl)ethenyl]-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole dictates the efficacy and safety of the final active pharmaceutical ingredient (API).”